124 related articles for article (PubMed ID: 26082022)
1. Therapeutic effect of Active Hexose-Correlated Compound (AHCC) combined with CpG-ODN (oligodeoxynucleotide) in B16 melanoma murine model.
Ignacio RM; Kim CS; Kim YD; Lee HM; Qi XF; Kim SK
Cytokine; 2015 Dec; 76(2):131-137. PubMed ID: 26082022
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model.
Cho HC; Kim BH; Kim K; Park JY; Chang JH; Kim SK
Int Immunopharmacol; 2008 Oct; 8(10):1401-7. PubMed ID: 18687302
[TBL] [Abstract][Full Text] [Related]
3. Ameliorating effect of CpG-ODN (oligodeoxynucleotide) against radiation-induced lung injury in mice.
Park K; Dhupal M; Kim CS; Jung SH; Choi D; Qi XF; Kim SK; Lee JY
Radiat Environ Biophys; 2020 Nov; 59(4):733-741. PubMed ID: 32914274
[TBL] [Abstract][Full Text] [Related]
4. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice.
Switaj T; Jalili A; Jakubowska AB; Drela N; Stoksik M; Nowis D; Basak G; Golab J; Wysocki PJ; Mackiewicz A; Sasor A; Socha K; Jakóbisiak M; Lasek W
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4165-75. PubMed ID: 15217954
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
6. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses.
Gao Y; Zhang D; Sun B; Fujii H; Kosuna K; Yin Z
Cancer Immunol Immunother; 2006 Oct; 55(10):1258-66. PubMed ID: 16362410
[TBL] [Abstract][Full Text] [Related]
7. The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model.
Zhang M; Yin T; Lu Y; Feng H
Med Sci Monit; 2016 Apr; 22():1309-17. PubMed ID: 27092689
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.
Sfondrini L; Sommariva M; Tortoreto M; Meini A; Piconese S; Calvaruso M; Van Rooijen N; Bonecchi R; Zaffaroni N; Colombo MP; Tagliabue E; Balsari A
Int J Cancer; 2013 Jul; 133(2):383-93. PubMed ID: 23319306
[TBL] [Abstract][Full Text] [Related]
9. A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
Jia H; Guo J; Wang P; Sun K; Chen J; Ren W; Wei T; Yang Y; Li J; Liu X; Li R; Zhong J; Wang M; Tian Z; Feng Z; Zhao T
Int Immunopharmacol; 2020 Jun; 83():106397. PubMed ID: 32220805
[TBL] [Abstract][Full Text] [Related]
10. CpG oligodeoxynucleotide induces apoptosis and cell cycle arrest in A20 lymphoma cells via TLR9-mediated pathways.
Qi XF; Zheng L; Kim CS; Lee KJ; Kim DH; Cai DQ; Qin JW; Yu YH; Wu Z; Kim SK
Mol Immunol; 2013 Jul; 54(3-4):327-37. PubMed ID: 23357786
[TBL] [Abstract][Full Text] [Related]
11. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.
Ballas ZK; Krieg AM; Warren T; Rasmussen W; Davis HL; Waldschmidt M; Weiner GJ
J Immunol; 2001 Nov; 167(9):4878-86. PubMed ID: 11673492
[TBL] [Abstract][Full Text] [Related]
12. Active Hexose Correlated Compound (AHCC) promotes an intestinal immune response in BALB/c mice and in primary intestinal epithelial cell culture involving toll-like receptors TLR-2 and TLR-4.
Mallet JF; Graham É; Ritz BW; Homma K; Matar C
Eur J Nutr; 2016 Feb; 55(1):139-46. PubMed ID: 25596849
[TBL] [Abstract][Full Text] [Related]
13. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.
Ninalga C; Loskog A; Klevenfeldt M; Essand M; Tötterman TH
J Immunother; 2005; 28(1):20-7. PubMed ID: 15614041
[TBL] [Abstract][Full Text] [Related]
14. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor.
Yuan S; Qiao T; Chen W
Cancer Biother Radiopharm; 2011 Apr; 26(2):203-8. PubMed ID: 21539452
[TBL] [Abstract][Full Text] [Related]
15. Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial.
Terakawa N; Matsui Y; Satoi S; Yanagimoto H; Takahashi K; Yamamoto T; Yamao J; Takai S; Kwon AH; Kamiyama Y
Nutr Cancer; 2008; 60(5):643-51. PubMed ID: 18791928
[TBL] [Abstract][Full Text] [Related]
16. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
[TBL] [Abstract][Full Text] [Related]
17. Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers.
Nikoofal-Sahlabadi S; Matbou Riahi M; Sadri K; Badiee A; Nikpoor AR; Jaafari MR
Eur J Pharm Sci; 2018 Jul; 119():159-170. PubMed ID: 29660463
[TBL] [Abstract][Full Text] [Related]
18. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
19. Low-dose supplementation with active hexose correlated compound improves the immune response to acute influenza infection in C57BL/6 mice.
Nogusa S; Gerbino J; Ritz BW
Nutr Res; 2009 Feb; 29(2):139-43. PubMed ID: 19285605
[TBL] [Abstract][Full Text] [Related]
20. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
